中基長壽科學(00767.HK)擬收購亞洲綜合細胞庫100%股權
格隆匯8月4日丨中基長壽科學(00767.HK)公告，於2025年8月4日，公司（買方）與中國國際骨關節醫療集團有限公司（賣方）訂立一項不具法律約束力諒解備忘錄，據此，買方擬收購（由其本身或透過其全資附屬公司）而賣方擬出售亞洲綜合細胞庫有限公司（目標公司）股權總額的100%。
基於賣方提供的資料，目標公司主要從事細胞療法、細胞藥品的研發轉化和健康長壽管理服務。目標公司現時持有亞洲綜合細胞庫。亞洲綜合細胞庫是世界最大的國際自體免疫細胞庫，是世界領先唯一的FDA、AABB、PIC/S cGMP、Isber-IRL、FACT、CAP、ISBT 128標準的免疫細胞、幹細胞雙種類全體系國際臨牀細胞庫，解決世界上國際標準細胞數量過少及安全有效應用的難題，是世界領先的國際細胞轉化應用平臺，是世界細胞管理領先者。
亞洲綜合細胞庫是亞洲唯一美國FDA註冊認可的免疫細胞、幹細胞雙種類全體系國際臨牀細胞庫，是亞洲唯一ISBER-IRL認證的免疫細胞庫，代表亞洲綜合細胞庫從細胞收集、篩選、檢測、包裝、處理、儲存、標籤到運輸都符合美國FDA認可的國際標準，細胞管理在全球處於領先水準。亞洲綜合細胞庫位於香港，可儲存併合法應用，檢測、儲存流程和報告由香港衛生署認可的一級或二級醫務化驗師完成，並由一級醫務化驗師獨立覈實，再由實驗室總監雙重覆核流程，確保整個過程完全滿足或超越本地的法規要求和安全標準。亞洲綜合細胞庫已於2018年11月17日開始運營，擁有防癌早篩專利技術、NK細胞專利技術、幹細胞專利技術、軟骨細胞專利技術等，擁有22個先進醫療檢測平臺。基於賣方提供的資料，可以爲全球30萬人提供世界領先的免疫細胞儲存、防癌早篩、長壽醫學檢測、健康長壽管理服務和防癌、防衰、膝關節健康領域的細胞療法、細胞藥品研發轉化，未來可實現收入超過300億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
